Latest & greatest articles for chronic kidney disease

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on chronic kidney disease or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on chronic kidney disease and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for chronic kidney disease

121. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD)

KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) OFFICIAL JOURNAL OF THE INTERNATIONAL SOCIET Y OF NEPHROLOGY VOLUME 7 | ISSUE 1 | JULY 2017 www.kisupplements.org KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) KISU_v7_i1_COVER.indd 1 KISU_v7_i1_COVER.indd 1 31-05 (...) -2017 13:23:05 31-05-2017 13:23:05KDIGO 2017 CLINICAL PRACTICE GUIDELINE UPDATE FOR THE DIAGNOSIS, EVALUATION, PREVENTION, AND TREATMENT OF CHRONIC KIDNEY DISEASE–MINERAL AND BONE DISORDER (CKD-MBD) Kidney International Supplements (2017) 7, 1–59 1KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and TreatmentofChronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) 3 Tables and supplementary material 6 KDIGO Executive Committee 7 Reference keys 8 CKD

2017 National Kidney Foundation

122. KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) Full Text available with Trip Pro

KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD) KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) - American Journal of Kidney Diseases Email/Username: Password: Remember me Search Terms Search within Search Share (...) this page Access provided by Volume 70, Issue 6, Pages 737–751 KDOQI US Commentary on the 2017 KDIGO Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) x Tamara Isakova Affiliations Division of Nephrology and Hypertension, Department of Medicine and Center for Translational Metabolism and Health, Institute for Public Health and Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL

2017 National Kidney Foundation

123. Urinary Calcium Excretion and Risk of Chronic Kidney Disease in the General Population Full Text available with Trip Pro

Urinary Calcium Excretion and Risk of Chronic Kidney Disease in the General Population High urinary calcium excretion (UCaE) has been shown to lead to accelerated renal function decline in individuals with renal tubular diseases. It is not known whether this association also exists in the general population. Therefore, we investigated whether high UCaE is associated with risk of developing chronic kidney disease (CKD) in community-dwelling subjects.Urine samples of 5491 subjects who were free (...) of CKD at baseline and participated in the Prevention of Renal and Vascular End-Stage Disease study (a prospective, observational, general population-based cohort of Dutch men and women aged 28-75 years) were examined for UCaE. UCa concentration was measured in two 24-hour urine samples at baseline (1997-1998) by indirect potentiometry. UCaE was treated as a continuous variable and a categorical variable grouped according to sex-specific quintiles for UCaE. UCaE was compared with de novo development

2016 Kidney international reports

124. Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity—A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial Full Text available with Trip Pro

Oral Magnesium Supplementation in Chronic Kidney Disease Stages 3 and 4: Efficacy, Safety, and Effect on Serum Calcification Propensity—A Prospective Randomized Double-Blinded Placebo-Controlled Clinical Trial Chronic kidney disease (CKD) is associated with high cardiovascular morbidity and mortality. Recent evidence suggests that increases in both serum and intracellular magnesium (Mg) can slow or even prevent the development of vascular calcification seen in CKD. Serum calcification

2016 Kidney international reports Controlled trial quality: predicted high

125. Traditional Thermal Therapy with Indirect Moxibustion Decreases Renal Arterial Resistive Index in Patients with Chronic Kidney Disease. (Abstract)

Traditional Thermal Therapy with Indirect Moxibustion Decreases Renal Arterial Resistive Index in Patients with Chronic Kidney Disease. To evaluate the immediate effects of traditional local thermal therapy with indirect moxibustion on renal hemodynamics in patients with chronic kidney disease (CKD) by using Doppler ultrasonography (US).Examiner-blinded crossover study.Forty-three participants with CKD (mean age ± standard deviation [SD], 44 ± 15 years; estimated glomerular filtration rate (...) , 69.5 ± 25.5 mL/min per 1.73 m(2); 20 men and 23 women).Participants received three successive treatment sessions of indirect moxibustion bilaterally at BL 23, a crucial acupuncture point, in the session. In the control session, the examiner was blinded by using smoke and aroma produced by moxibustion performed in an ashtray placed near the patient's body.The main outcome measure was resistive index (RI) in the renal segmental arteries. Blood flow parameters, including RI, were measured for six

2016 Journal of alternative and complementary medicine (New York, N.Y.) Controlled trial quality: uncertain

126. Chronic Kidney Disease. (Abstract)

Chronic Kidney Disease. The definition and classification of chronic kidney disease (CKD) have evolved over time, but current international guidelines define this condition as decreased kidney function shown by glomerular filtration rate (GFR) of less than 60 mL/min per 1·73 m2, or markers of kidney damage, or both, of at least 3 months duration, regardless of the underlying cause. Diabetes and hypertension are the main causes of CKD in all high-income and middle-income countries, and also (...) is measured either via exogenous markers (eg, DTPA, iohexol), or estimated using equations. Presence of proteinuria is associated with increased risk of progression of CKD and death. Kidney biopsy samples can show definitive evidence of CKD, through common changes such as glomerular sclerosis, tubular atrophy, and interstitial fibrosis. Complications include anaemia due to reduced production of erythropoietin by the kidney; reduced red blood cell survival and iron deficiency; and mineral bone disease

2016 Lancet

127. Metabolically Healthy Obesity and Development of Chronic Kidney Disease Full Text available with Trip Pro

Metabolically Healthy Obesity and Development of Chronic Kidney Disease 27842407 2017 12 07 2018 12 02 1539-3704 165 10 2016 11 15 Annals of internal medicine Ann. Intern. Med. Metabolically Healthy Obesity and Development of Chronic Kidney Disease. 743 10.7326/L16-0407 Kahn Henry S HS From Centers for Disease Control and Prevention, Atlanta, Georgia. Pavkov Meda E ME From Centers for Disease Control and Prevention, Atlanta, Georgia. eng CC999999 Intramural CDC HHS United States Journal Article (...) Comment United States Ann Intern Med 0372351 0003-4819 AIM IM Ann Intern Med. 2016 Mar 1;164(5):305-12 26857595 Ann Intern Med. 2016 Nov 15;165(10 ):744-745 27842405 Body Mass Index Humans Obesity Obesity, Metabolically Benign Renal Insufficiency, Chronic 2016 11 15 6 0 2016 11 15 6 0 2017 12 8 6 0 ppublish 27842407 2582915 10.7326/L16-0407 PMC5308792 NIHMS848359 Int J Obes (Lond). 2016 May;40(5):883-6 26841729 PLoS One. 2016 Jan 05;11(1):e0146057 26731527 Ann Intern Med. 2016 Mar 1;164(5):305-12

2016 Annals of Internal Medicine

128. Sarcopenia, Obesity, and Mortality in US Adults With and Without Chronic Kidney Disease Full Text available with Trip Pro

Sarcopenia, Obesity, and Mortality in US Adults With and Without Chronic Kidney Disease In pre-dialysis chronic kidney disease (CKD), the association of muscle mass with mortality is poorly defined, and no study has examined outcomes related to the co-occurrence of low muscle mass and excess adiposity (sarcopenic-obesity). Methods: We examined abnormalities of muscle and fat mass in adult participants of the National Health and Nutrition Examination Survey 1999-2004. We determined whether

2016 Kidney international reports

129. Downregulation of AdipoR1 is Associated with increased Circulating Adiponectin Levels in Serbian Chronic Kidney Disease Patients Full Text available with Trip Pro

Downregulation of AdipoR1 is Associated with increased Circulating Adiponectin Levels in Serbian Chronic Kidney Disease Patients Since the rise in plasma adiponectin levels in chronic kidney disease (CKD) patients has not yet been elucidated, we sought to investigate if patients on hemodialysis (HD) have altered expression of adiponectin receptors in peripheral blood mononuclear cells (PBMCs) compared to healthy subjects.This study included 31 patients with chronic kidney disease on HD and 33

2016 Journal of medical biochemistry

130. Hypertension Control, Apparent Treatment Resistance, and Outcomes in the Elderly Population With Chronic Kidney Disease Full Text available with Trip Pro

Hypertension Control, Apparent Treatment Resistance, and Outcomes in the Elderly Population With Chronic Kidney Disease Chronic kidney disease (CKD) is often associated with poor hypertension control and treatment resistance, but whether CKD modifies the effect of hypertension control on outcomes is unknown.We studied 10-year mortality and cardiovascular events according to hypertension control status and CKD (glomerular filtration rate <60 ml/min/1.73m2) in 4262 community-dwelling individuals

2016 Kidney international reports

131. Tackling the Fallout From Chronic Kidney Disease of Unknown Etiology: Why We Need to Focus on Providing Peritoneal Dialysis in Rural, Low-Resource Settings Full Text available with Trip Pro

Tackling the Fallout From Chronic Kidney Disease of Unknown Etiology: Why We Need to Focus on Providing Peritoneal Dialysis in Rural, Low-Resource Settings 29142936 2018 11 13 2468-0249 2 1 2017 Jan Kidney international reports Kidney Int Rep Tackling the Fallout From Chronic Kidney Disease of Unknown Etiology: Why We Need to Focus on Providing Peritoneal Dialysis in Rural, Low-Resource Settings. 1-4 10.1016/j.ekir.2016.10.004 Nanayakkara Nishanthe N Department of Medicine, Teaching Hospital (...) , Kandy, Sri Lanka. Wazil A W M AWM Department of Medicine, Teaching Hospital, Kandy, Sri Lanka. Gunerathne Lishanthe L Department of Medicine, Renal Care and Research Unit, Girandurukotte, Sri Lanka. Dickowita Sewmini S Department of Medicine, Teaching Hospital, Kandy, Sri Lanka. Rope Robert R Department of Medicine, Division of Nephrology, Stanford University School of Medicine, Palo Alto, California, USA. Ratnayake Charaka C Department of Medicine, Teaching Hospital, Kandy, Sri Lanka. Saxena Anjali

2016 Kidney international reports

132. Timely Referral to Outpatient Nephrology Care Slows Progression and Reduces Treatment Costs of Chronic Kidney Diseases Full Text available with Trip Pro

Timely Referral to Outpatient Nephrology Care Slows Progression and Reduces Treatment Costs of Chronic Kidney Diseases We present a new approach to evaluate the importance of ambulatory nephrology care in patients with chronic kidney disease (CKD).An anonymized health claims database of German insurance companies was searched in a retrospective analysis for patients with CKD using the codes of the International Classification of Diseases, 10th German modification. A total of 105,219 patients (...) with CKD were identified. Patients were assigned to the group "timely referral," when nephrology care was present in the starting year 2009, or initiated during the following 3 years in CKD1-4. Using frequency matching for age and gender, 21,024 of the late referral group were matched with the equal number of patients in the timely referral group. Hospital admission rates, total treatment costs, and kidney function (change in CKD stages, start of dialysis, mortality) were documented each year during

2016 Kidney international reports

133. Interventions for chronic kidney disease in people with sickle cell disease. Full Text available with Trip Pro

Interventions for chronic kidney disease in people with sickle cell disease. This is the protocol for a review and there is no abstract. The objectives are as follows: To assess the effectiveness of any intervention in preventing or reducing kidney complications or CKD in people with SCD (including red blood cell transfusions, hydroxyurea and ACEI (either alone or in combination with each other)).

2016 Cochrane

134. The Green Tea Polyphenol(—)-epigallocatechin-3-gallate and its beneficial roles in chronic kidney disease Full Text available with Trip Pro

The Green Tea Polyphenol(—)-epigallocatechin-3-gallate and its beneficial roles in chronic kidney disease Chronic kidney disease (CKD), a condition that affects around 10% of the population, has become a significant public health concern. Current therapeutic strategies to slow down the progression of CKD remain limited. Thus, it is urgent to develop new strategies to manage the patients with CKD. Work within the past decade has improved our understanding of the mechanisms contributing to CKD (...) . In particular, oxidative stress as well as inflammation appears to play a pivotal role in CKD progression. ()-Epigallocatechin-3-gallate (EGCG), the major catechin of green tea extract, is known as a powerful antioxidant and reactive oxygen species scavenger. Various studies have shown EGCG has a potential role in chronic kidney disease models. It is suggested that EGCG modulates cellular and molecular mechanisms via inflammation-related NF-кB and Nrf2 signaling pathway, as well as apoptosis-related ER

2016 Journal of translational internal medicine

135. Sevelamer for the Treatment of Patients with Chronic Kidney Disease: A Review of Clinical and Cost-Effectiveness

scenarios involving patients in CKD stages 3 to 5D. In addition, sevelemar is cheaper and more clinically effective than calcium-carbonate in all scenarios involving a subset of pre-dialysis or NDD-CKD patients. Tags kidney, kidney diseases, polyamines, Chronic Renal Disease, Chronic Renal Failure, Sevelamer Files Rapid Response Summary with Critical Appraisal Published : September 21, 2016 Follow us: © 2019 Canadian Agency for Drugs and Technologies in Health Get our newsletter: (...) Sevelamer for the Treatment of Patients with Chronic Kidney Disease: A Review of Clinical and Cost-Effectiveness Sevelamer for the Treatment of Patients with Chronic Kidney Disease: A Review of Clinical and Cost-Effectiveness | CADTH.ca Find the information you need Sevelamer for the Treatment of Patients with Chronic Kidney Disease: A Review of Clinical and Cost-Effectiveness Sevelamer for the Treatment of Patients with Chronic Kidney Disease: A Review of Clinical and Cost-Effectiveness

2016 Canadian Agency for Drugs and Technologies in Health - Rapid Review

136. Depression in Chronic Kidney Disease and End-Stage Renal Disease: Similarities and Differences in Diagnosis, Epidemiology, and Management Full Text available with Trip Pro

Depression in Chronic Kidney Disease and End-Stage Renal Disease: Similarities and Differences in Diagnosis, Epidemiology, and Management Depression is highly prevalent and is associated with poor quality of life and increased mortality among adults with chronic kidney disease (CKD), including those with end-stage renal disease (ESRD). However, there are several important differences in the diagnosis, epidemiology, and management of depression between patients with non-dialysis-dependent CKD

2016 Kidney international reports

137. Evaluation of Renal Blood Flow in Chronic Kidney Disease Using Arterial Spin Labeling Perfusion Magnetic Resonance Imaging Full Text available with Trip Pro

Evaluation of Renal Blood Flow in Chronic Kidney Disease Using Arterial Spin Labeling Perfusion Magnetic Resonance Imaging Chronic kidney disease (CKD) is known to be associated with reduced renal blood flow. However, data to-date in humans is limited.In this study, non-invasive arterial spin labeling (ASL) MRI data was acquired in 33 patients with diabetes and stage-3 CKD, and 30 healthy controls.A significantly lower renal blood flow both in cortex (108.4±36.4 vs. 207.3±41.8; p<0.001, d=2.52 (...) to separate healthy and CKD was estimated to be Cor_BF=142.9 and Med_BF=24.1.These results support the use of ASL in the evaluation of renal blood flow in patients with moderate level of CKD. Whether these measurements can identify subjects at risk of progressive CKD requires further longitudinal follow-up.

2016 Kidney international reports

138. Iron (III) isomaltoside 1000 (Diafer) - iron deficiency in adults with chronic kidney disease (CKD) on dialysis

Iron (III) isomaltoside 1000 (Diafer) - iron deficiency in adults with chronic kidney disease (CKD) on dialysis 1 Published 13 February 2017 Re-submission iron III isomaltoside 1000 (contains 50mg iron per mL) (Diafer ® ), solution for injection SMC No. (1177/16) Pharmacosmos UK Limited 13 January 2017 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in Scotland (...) . The advice is summarised as follows: ADVICE: following a resubmission iron III isomaltoside 1000 5% (Diafer ® ) is accepted for use within NHS Scotland. Indication under review: For the treatment of iron deficiency in adults with chronic kidney disease (CKD) on dialysis, when oral iron preparations are ineffective or cannot be used. Iron III isomaltoside 1000 at a higher (10%) concentration has been shown to be non-inferior to another intravenous iron product in maintaining haemoglobin concentration

2016 Scottish Medicines Consortium

139. Efficacy of Folic Acid Therapy on the Progression of Chronic Kidney Disease: The Renal Substudy of the China Stroke Primary Prevention Trial Full Text available with Trip Pro

Efficacy of Folic Acid Therapy on the Progression of Chronic Kidney Disease: The Renal Substudy of the China Stroke Primary Prevention Trial The efficacy of folic acid therapy on renal outcomes has not been previously investigated in populations without folic acid fortification.To test whether treatment with enalapril and folic acid is more effective in slowing renal function decline than enalapril alone across a spectrum of renal function at baseline from normal to moderate chronic kidney (...) was the progression of CKD, defined as a decrease in eGFR of 30% or more and to a level of less than 60 mL/min/1.73 m2 if the baseline eGFR was 60 mL/min/1.73 m2 or more, or a decrease in eGFR of 50% or more if the baseline eGFR was less than 60 mL/min/1.73 m2; or end-stage renal disease. Secondary outcomes included a composite of the primary outcome and all-cause death, rapid decline in renal function, and rate of eGFR decline.Overall, 15 104 Chinese adults with a mean (range) age of 60 (45-75) years were

2016 EvidenceUpdates Controlled trial quality: predicted high

140. Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort Full Text available with Trip Pro

Lipidomic Signature of Progression of Chronic Kidney Disease in the Chronic Renal Insufficiency Cohort Human studies report conflicting results on the predictive power of serum lipids on progression of chronic kidney disease (CKD). We aimed to systematically identify the lipids that predict progression to end-stage kidney disease.From the Chronic Renal Insufficiency Cohort, 79 patients with CKD stage 2 to 3 who progressed to ESKD over 6 years of follow up were selected and frequency-matched

2016 Kidney international reports Controlled trial quality: uncertain